Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality; · Ventilator‐associated pneumonia
Monotherapy showed no clear difference in all‐cause mortality; compared with combination therapy (moderate certainty).
1 finding from 1 review
Clinical cure · Ventilator‐associated pneumonia
It is very uncertain whether monotherapy changes clinical cure (ITT) compared with combination therapy (very low certainty).
2 findings from 1 review
Adverse events · Ventilator‐associated pneumonia
Monotherapy showed no clear difference in adverse events compared with combination therapy (moderate certainty).
1 finding from 1 review
Duration of ICU stay · Ventilator‐associated pneumonia
1 finding from 1 review
Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · patients with muscle cramps
1 finding from 1 review
Major adverse events · patients with muscle cramps
1 finding from 1 review
Minor adverse events · patients with muscle cramps
1 finding from 1 review
Number of cramps over 2 weeks · patients with muscle cramps
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Time to next exacerbation · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
1 finding from 1 review
Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
1 finding from 1 review
Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).
1 finding from 1 review